We would like to thank Pieter Smits, one of our steering committee member of the PIONEER IV trial for sharing the fundamentals of the Healing-Targeted Supreme stent at the #ENCORE congress in Seoul! This contemporary #DES is designed to boost #EarlyFunctionalHealing through: - An unique drug release kinetics: we minimize the contamination of tissue by the drug and the delay in endothelial cell migration through rapid drug release. - Re-endothelialization booster: our coating is based on a nanometric #ElectroGrafted primer layer which accelerates healing. Through evidence supported by pre-clinical, imaging and clinical trials of 5000+ patients worldwide, we at SINOMED continuously strives to deliver a its best-in-class device for patients ensuring the safest outcomes. Latest ongoing post-market clinical program #PIONEER IV an investigator initiated University of Galway sponsored trial, led by Prof.Patrick Serruys and centrally managed by CORRIB Research Centre for Advanced Imaging and Core Laboratory, is an exciting all-comers study which will have a special focus the healing profile of the device, evaluating the clinical outcomes of 1-Month DAPT regimen post PCI among 2500+ patients. The expected MFDS approval of #HTSupreme #DES is anticipated to be Q2 2024 in South-Korea. #ElectroGrafting is a technology developed by AlchiMedics S.A.S. under license from CEA” Contact us or scan below to learn more about #HTSupreme and this presentation.
Regional Sales Manager at Digital Imaging System (Abbott Vascular)
1yAnticipating MFDS approval of the HTSupreme DES in South Korea in Q2 2024 is a significant milestone. It's clear that SINOMED is committed to delivering the best-in-class medical devices for patients... 👌